FindTrial
Sign In

Surgical Outcomes After Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma: Propensity-Matched Comparison of Different Curative Strategies Following TKIs plus Anti-PD-1 antibodies +/- Interventional Therapy

Surgical Outcomes After Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma: Propensity-Matched Comparison of Different Curative Strategies Following TKIs plus Anti-PD-1 antibodies +/- Interventional Therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120016
Enrollment
Unknown
Registered
2026-03-08
Start date
2026-03-15
Completion date
Unknown
Last updated
2026-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Observational group:None

Sponsors

SUN YAT-SEN MEMORIAL HOSPITAL
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18. 2. ECOG PS 0-1; Child-Pugh A/B. 3. Initially unresectable HCC, confirmed by postoperative pathology. 4. >=1 target lesion evaluable per mRECIST. 5. Dual/triple conversion therapy: TKIs + PD-1 inhibitors +/- intervention. 6. Enhanced CT/MRI within 2 months pre-treatment. 7. First radical hepatectomy. 8. R0 resection.

Exclusion criteria

Exclusion criteria: 1. Concurrent malignancies. 2. Non-radical surgery. 3. Liver transplantation. 4. Lymph node or extrahepatic metastasis. 5. Non-initial surgery. 6. Incomplete medical records or loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Disease-free survival, overall survival, textbook outcome;—

Secondary

MeasureTime frame
Overall survival;Textbook outcome;—

Countries

China

Contacts

Public ContactShang Changzhen

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

shchzh2@mail.sysu.edu.cn+86 20 34070701

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026